



**AGENDA**  
**Pharmaceuticals & Therapeutics Committee**  
**Department of Health Care Policy & Financing**

Zoom Webinar

[https://magellanhealth.zoom.us/webinar/register/WN\\_vbolGv6FQYmuy6HTGo9-9Q](https://magellanhealth.zoom.us/webinar/register/WN_vbolGv6FQYmuy6HTGo9-9Q)

Tuesday, October 5, 2021, 1:00-5:00 P.M.

## 1. Committee Member Introductions

James Feinstein, MD, Chairperson

Gwen Black, PharmD, Vice Chair

Lynn Parry, MD

Kimberley Jackson, DO

Marisa Wiktor, MD

David Elwell, MD

Kelet Robinson, MD

Emily Kosirog, PharmD

Thuy McKittrick, PharmD

Daralyn Morgenson, PharmD

Davin Patel, PharmD

## 2. Unfinished Business and General Orders

Approval of minutes from July 13, 2021 P&T meeting

Updates from July 13, 2021 P&T Meeting

Anticonvulsants, Oral

Stimulants and Related Agents

Estrogen Agents

- Injectable
- Oral/Transdermal

Contraceptives

- Oral
- Topical

Diabetes Management Classes

- GLP-1 Analogues
- Other Hypoglycemic Combinations
- SGLT-2is & Combinations

Glucagon Agents

Anticoagulants, Oral

Antiplatelet Agents

Colony Stimulating Factors

Newer Hereditary Angioedema (HAE) Products

Overactive Bladder (OAB) Agents

Ophthalmics, Immunomodulators



Mass review drug classes:

Bone Resorption Suppression and Related Agents

- Bisphosphonates
- Non-Bisphosphonates

Diabetes Management Classes

- Amylin
- Biguanides
- DPP-4is & Combinations
- Insulins & Related Agents
- Meglitinides & Combinations
- TZDs & Combinations

GI Motility, Chronic

Anticoagulants, Parenteral

Erythropoiesis Stimulating Agents (ESAs)

Prenatal Vitamins/Minerals

### 3. New Business

Updates from the Prior Authorization Call Center

### 4. Drug Classes Up for Review

Review of Hepatitis C Virus Treatments - Direct-Acting Antivirals (DAAs)

Review of Human Immunodeficiency Virus Treatments, Oral

- Single-Ingredient
- Two-Ingredient
- Other Combinations

Pulmonary Arterial Hypertension (PAH) Therapies

- Phosphodiesterase Inhibitors
- Endothelin Antagonists
- Prostanoids
- Guanylate Cyclase (sGC) Stimulators

Review of Antidepressants - Newer Generation Agents

Review of Triptans and Other Migraine Agents\*

- Oral
- Non-Oral

Review of Antiemetics

- Oral
- Non-Oral

Review of H. Pylori Treatments

Review of Targeted Immune Modulators

Review of Respiratory Agents

- Inhaled Anticholinergics & Combinations

Improving health care equity, access and outcomes for the people we serve while saving Coloradans money on health care and driving value for Colorado.

[www.colorado.gov/hcpf](http://www.colorado.gov/hcpf)



- Short-Acting & Long-Acting Beta-Agonists (SABAs & LABAs)
- Inhaled Corticosteroids & Combinations

*\*Extracted from Mass Review*

Mass review drug classes:

- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  - Oral
  - Non-Oral
- Antibiotics, Inhaled
- Anti-herpetic Agents
  - Oral
  - Topical
- Fluoroquinolones, Oral
- Hepatitis C Virus Treatments - Ribavirin Products
- Antidepressants
  - Monoamine Oxidase Inhibitors (MAOIs)
  - Tricyclics
- Antipsoriatics
  - Oral
  - Topical
- Topical Immunomodulators
- Topical Steroids
  - Low Potency
  - Medium Potency
  - High Potency
  - Very High Potency
- Pancreatic Enzymes
- Proton Pump Inhibitors (PPIs)
- Non-Biologic Ulcerative Colitis Agents
  - Oral
  - Rectal
- Immune Globulins
- Newer Generation Antihistamines
- Antihistamine/Decongestant Combinations
- Intranasal Rhinitis Agents
- Leukotriene Modifiers
- Methotrexate Products
- Epinephrine Products
- Newer Hereditary Angioedema (HAE) Agents
- Antihyperuricemics
- Respiratory Agents - Phosphodiesterase Inhibitors (PDEIs)



Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:

- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical testimony that will be presented for P&T Committee dissemination.
- Advance notice requests to present and/or written public comments can be submitted to Jessica Czechowski, Pharmacist Account Executive, [jlczehowski@magellanhealth.com](mailto:jlczehowski@magellanhealth.com) and carbon copy: Brittany Schock, PDL Pharmacist, [brittany.schock@state.co.us](mailto:brittany.schock@state.co.us). Once approved, public comments will be distributed to P&T Committee Members. Due to Virtual venue change, requests and public comment summaries are due by **September 28<sup>th</sup>, 2021 by 5pm MST.**

## 5. Adjourn

Upcoming Meeting Date: Tuesday, January 11, 2022

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](#) or [hcpf504ada@state.co.us](mailto:hcpf504ada@state.co.us) at least one week prior to the meeting to make arrangements.

